Minimally Invasive Glaucoma Surgery Devices Market by Device Type, Surgical Site, Indication, Surgical Approach, Procedure Type, Device Class, Payment Method, Patient Type, Usability, End User, Distribution Channel

List of Tables

The Minimally Invasive Glaucoma Surgery Devices Market is projected to grow by USD 944.80 million at a CAGR of 5.82% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 635.51 million
Estimated Year [2026]	USD 671.86 million
Forecast Year [2032]	USD 944.80 million
CAGR (%)	5.82%

Minimally invasive glaucoma surgery devices are reshaping glaucoma management by offering a lower-trauma surgical option between topical medication, laser therapy, and conventional trabeculectomy or tube shunt surgery. The clinical need is substantial: peer-reviewed epidemiology estimates that approximately 76 million people aged 40 to 80 had glaucoma in 2020, with prevalence projected to reach 111.8 million by 2040.

MIGS adoption is supported by aging populations, rising cataract surgery volumes, and demand for procedures that can reduce intraocular pressure and medication burden while preserving safety. Growth in clinical use is strongest where ophthalmologists have access to reimbursed devices, modern ambulatory surgery infrastructure, optical coherence tomography, gonioscopy-based surgical training, and longitudinal glaucoma monitoring.

Transformative Shifts Reshaping MIGS Adoption

The MIGS landscape is moving from a cataract-combination niche toward broader procedural glaucoma care. Trabecular micro-bypass stents, canaloplasty systems, goniotomy devices, subconjunctival implants, and suprachoroidal approaches are competing on durability, safety profile, ease of implantation, and fit within ophthalmic surgery workflows.

Key shifts include earlier intervention in mild-to-moderate open-angle glaucoma, greater attention to medication adherence challenges, and stronger post-market evidence requirements. Regulatory scrutiny, surgeon training, reimbursement coding, and comparative outcomes versus selective laser trabeculoplasty and conventional filtration surgery are now central to commercial success in the minimally invasive glaucoma surgery devices landscape.

Cumulative Impact of AI on Glaucoma Surgery Pathways

Artificial intelligence is increasingly cumulative across the glaucoma care pathway rather than limited to device design. AI-enabled analysis of OCT, fundus imaging, visual fields, and electronic health records can support risk stratification, progression detection, referral prioritization, and selection of patients who may benefit from minimally invasive glaucoma surgery.

AI also improves operational efficiency by helping clinics manage follow-up intervals and identify nonadherence risk. However, adoption depends on validated datasets, explainability, cybersecurity, and regulatory compliance. In MIGS, the near-term impact is strongest in diagnostics, surgical planning, outcomes tracking, real-world evidence generation, and post-procedure monitoring of intraocular pressure control.

Regional Dynamics Across Global MIGS Markets

North America remains a leading region for minimally invasive glaucoma surgery device commercialization due to FDA-cleared technologies, high cataract procedure volumes, glaucoma subspecialty networks, and established ambulatory surgery centers in the United States and Canada. Europe benefits from advanced ophthalmology infrastructure across major health systems, while the Medical Device Regulation has increased requirements for clinical evidence, post-market surveillance, and technical documentation.

Asia-Pacific offers major long-term clinical potential because glaucoma prevalence rises with aging, urbanization, diabetes comorbidity, and expanding eye-care access in China, India, Japan, South Korea, and Australia. Japan, Australia, and South Korea support advanced ophthalmic procedures through specialist capacity and structured health systems, while China and India combine large glaucoma populations with expanding private and public eye-care networks.

Latin America, the Middle East, and Africa show demand linked to unmet glaucoma diagnosis and treatment needs, but affordability, specialist density, surgical training access, and reimbursement variability shape adoption speed. Brazil and Mexico anchor Latin American uptake through private ophthalmology centers; GCC countries in the Middle East benefit from investment in tertiary hospitals; and Africa's adoption is constrained by late diagnosis, limited glaucoma specialist availability, and uneven access to surgical infrastructure.

Group-Level Demand Patterns and Policy Signals

The European Union is defined by harmonized but more rigorous device regulation, favoring manufacturers with strong clinical evidence, quality systems, and post-market surveillance. G7 markets concentrate premium ophthalmic spending, surgeon training capacity, established cataract surgery workflows, and early adoption of data-driven glaucoma care, making evidence quality and reimbursement alignment decisive for minimally invasive glaucoma surgery device uptake.

BRICS countries represent large patient pools and expanding private ophthalmology networks, especially in China, India, and Brazil, while Russia is more affected by procurement limitations and geopolitical constraints. ASEAN markets are heterogeneous, with Singapore, Thailand, and Malaysia supporting advanced procedures sooner than lower-income systems, where affordability and specialist availability remain key barriers.

GCC countries benefit from specialty hospital investment, medical tourism strategies, and public-sector modernization programs that can support premium ophthalmic technologies when clinical value is demonstrated. NATO countries overlap with many high-income markets where procurement standards, supply-chain resilience, cybersecurity, and regulatory compliance are increasingly relevant for AI-enabled glaucoma diagnostics, surgical planning platforms, and connected post-market data systems.

Country-Level Adoption Signals

The United States is a pivotal minimally invasive glaucoma surgery device market because of FDA pathways, Medicare-linked reimbursement, high glaucoma diagnosis volumes, and extensive ambulatory surgery center use. Canada follows evidence-based adoption through provincial health systems and specialist ophthalmology networks, while Mexico and Brazil show private-sector momentum alongside persistent access gaps in public glaucoma care.

In Europe, the United Kingdom, Germany, France, Italy, and Spain emphasize clinical value, cost-effectiveness, safety documentation, and compliance with EU or domestic device rules. Germany and France have strong specialist infrastructure, the United Kingdom places significant weight on health technology assessment and guideline alignment, Italy and Spain combine advanced ophthalmology centers with regional reimbursement differences, and Russia remains influenced by procurement constraints, import dynamics, and geopolitical pressures.

China and India offer scale because of large aging populations and expanding eye-care infrastructure, though reimbursement, surgeon training, and affordability shape device selection. Japan prioritizes quality, safety, and clinical evidence, Australia supports specialist uptake through advanced ophthalmology networks, and South Korea combines high procedural sophistication with strong medical technology capabilities, creating favorable conditions for glaucoma imaging, surgical innovation, and post-procedure monitoring.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize rigorous comparative evidence, including intraocular pressure reduction, medication reduction, adverse events, retreatment rates, visual field stability, endothelial cell safety, and quality-of-life outcomes. Real-world registries and long-term follow-up are essential because payers, regulators, and surgeons increasingly demand durable value beyond short pivotal trials.

Commercial strategies should align device design with surgeon learning curves, procedure time, reimbursement codes, cataract workflow integration, and glaucoma severity segmentation. Organizations should also invest in AI-ready data infrastructure, physician education, market-access dossiers, health economic evidence, and region-specific pricing models for high-growth but cost-sensitive markets.

Evidence-Based Research Methodology

This executive summary is grounded in triangulated secondary research from peer-reviewed glaucoma epidemiology, public health agencies such as the World Health Organization, regulatory sources including the FDA and European authorities, ophthalmology guidelines, reimbursement information, clinical literature, and publicly available policy documents.

The analysis evaluates device categories, clinical indications, regional healthcare infrastructure, demographic demand, competitive positioning, regulatory expectations, and policy signals. Emphasis is placed on verified trends rather than speculative market claims, with qualitative interpretation anchored to documented disease burden, regulatory pathways, clinical evidence requirements, and observed adoption drivers.

Conclusion: MIGS Moves Toward Earlier, Data-Guided Care

Minimally invasive glaucoma surgery devices are becoming an important part of modern glaucoma care as clinicians seek safer, earlier, and more workflow-compatible interventions for open-angle glaucoma and cataract-associated surgical pathways. Adoption is supported by a large global glaucoma burden, aging demographics, increased diagnostic imaging use, and the need to reduce long-term dependence on topical medications.

Future leadership will depend on evidence quality, reimbursement alignment, surgeon confidence, regulatory readiness, and integration with AI-enabled diagnostics and outcomes monitoring. Device developers and healthcare stakeholders that combine clinical durability, accessible training, and region-specific market strategies will be best positioned in the evolving minimally invasive glaucoma surgery device ecosystem.

Product Code: MRR-036C5CF3A869

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Minimally Invasive Glaucoma Surgery Devices Market, by Device Type

7.1. Ablation Tools
7.2. Catheter
7.3. Lumen-Based Shunts
- 7.3.1. Fixed-Lumen
- 7.3.2. Flow-Controlled
7.4. Scaffold/Expander
7.5. Stents

8. Minimally Invasive Glaucoma Surgery Devices Market, by Surgical Site

8.1. Ciliary Body
8.2. Schlemm's Canal
8.3. Subconjunctival Space
8.4. Suprachoroidal Space
8.5. Trabecular Meshwork

9. Minimally Invasive Glaucoma Surgery Devices Market, by Indication

9.1. Angle-Closure Glaucoma
9.2. Congenital Glaucoma
9.3. Primary Open Angle Glaucoma
9.4. Secondary Glaucoma

10. Minimally Invasive Glaucoma Surgery Devices Market, by Surgical Approach

10.1. Ab Externo
10.2. Ab Interno

11. Minimally Invasive Glaucoma Surgery Devices Market, by Procedure Type

11.1. Combined With Cataract Surgery
11.2. Standalone Procedure

12. Minimally Invasive Glaucoma Surgery Devices Market, by Implant Material

12.1. Metals
- 12.1.1. Nitinol
- 12.1.2. Titanium
12.2. Polymers
- 12.2.1. Gelatin
- 12.2.2. Polyethersulfone
- 12.2.3. Polyimide
- 12.2.4. Silicone

13. Minimally Invasive Glaucoma Surgery Devices Market, by Device Class

13.1. Implantable
13.2. Non-implantable

14. Minimally Invasive Glaucoma Surgery Devices Market, by Payment Method

14.1. Reimbursement-Based
14.2. Self-Pay

15. Minimally Invasive Glaucoma Surgery Devices Market, by Patient Type

15.1. Pediatric
15.2. Adult

16. Minimally Invasive Glaucoma Surgery Devices Market, by Usability

16.1. Reusable
16.2. Disposable

17. Minimally Invasive Glaucoma Surgery Devices Market, by End User

17.1. Ambulatory Surgery Centers
17.2. Ophthalmic Clinics
17.3. Specialty Eye Hospitals

18. Minimally Invasive Glaucoma Surgery Devices Market, by Distribution Channel

18.1. Offline
18.2. Online

19. Minimally Invasive Glaucoma Surgery Devices Market, by Region

19.1. Asia-Pacific
19.2. North America
19.3. Latin America
19.4. Europe
19.5. Middle East
19.6. Africa

20. Minimally Invasive Glaucoma Surgery Devices Market, by Group

20.1. ASEAN
20.2. GCC
20.3. European Union
20.4. BRICS
20.5. G7
20.6. NATO

21. Minimally Invasive Glaucoma Surgery Devices Market, by Country

21.1. United States
21.2. Canada
21.3. Mexico
21.4. Brazil
21.5. United Kingdom
21.6. Germany
21.7. France
21.8. Russia
21.9. Italy
21.10. Spain
21.11. China
21.12. India
21.13. Japan
21.14. Australia
21.15. South Korea

22. Competitive Landscape

22.1. Market Concentration Analysis, 2025
- 22.1.1. Concentration Ratio (CR)
- 22.1.2. Herfindahl Hirschman Index (HHI)
22.2. Recent Developments & Impact Analysis, 2025
22.3. Product Portfolio Analysis, 2025
22.4. Benchmarking Analysis, 2025

23. Company Profiles

23.1. AbbVie Inc.
23.2. Alcon Vision LLC
23.3. Avisi Technologies, Inc.
23.4. Bausch + Lomb Corp.
23.5. BVI Medical, Inc.
23.6. Chengdu Kanghong Pharmaceutical Group Co., Ltd.
23.7. Corza Ophthalmology Products, Inc.
23.8. Glaukos Corporation
23.9. Haag-Streit Group by Metall Zug AG
23.10. Iridex Corporation
23.11. iSTAR Medical
23.12. Johnson & Johnson Services, Inc.
23.13. Lantrek, Inc.
23.14. LIQID Medical (Pty) Ltd.
23.15. Lumenis Be Ltd.
23.16. Lumibird Medical
23.17. New World Medical, Inc.
23.18. Nova Eye Medical Limited
23.19. Oertli Instrumente AG
23.20. Rheon Medical SA
23.21. Santen Pharmaceutical Co., Ltd.
23.22. Sight Sciences, Inc.
23.23. Ziemer Ophthalmic Systems AG